Real-World Data shows Efficacy of Vildagliptin- Dapagliflozin FDC among High-CV Risk T2D in Indian Cardiology Settings

Real-World Data shows Efficacy of Vildagliptin- Dapagliflozin FDC among High-CV Risk T2D in Indian Cardiology Settings

DAa-ViNCI Study: Real-World Data shows Efficacy of Vildagliptin- Dapagliflozin FDC among High-CV Risk T2D in Indian Cardiology Settings We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link

Read More
Findings from Latest DAa-ViNCI Study

Findings from Latest DAa-ViNCI Study

Vildagliptin-Dapagliflozin FDC Effective in High CV Risk Indian T2DM Patients: Findings from Latest DAa-ViNCI Study We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link

Read More